Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Атопический дерматит

Список литературы

  1. Голдсмит Л.А., Кац С.И., Джилкрест Б.А. и др.; пер. С англ.; общ. ред. Потекаева Н.Н., Львова А.Н. - изд. 2-е, Издательство Панфилова, 2015 - Дерматология Фицпатрика в клинической практике - Т. 1, стр. 182-200.
  2. Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014 Oct;134(4):769-79.
  3. Hill DA, Spergel JM. The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018 Feb;120(2):131-137. doi: 10.1016/j.anai.2017.10.037. Review. Erratum in: Ann Allergy Asthma Immunol. 2018 Mar 9;:. PubMed PMID: 29413336; PubMed Central PMCID: PMC5806141.
  4. Wollenberg A, Frank R, Kroth J, Ruzicka T. Proactive therapy of atopic eczema - an evidence-based concept with a behavioral background. J Dtsch Dermatol Ges 2009; 7: 117-121. 107.
  5. Weidinger S, Novak N. Atopic dermatitis. Lancet Lond Engl 2016;387(10023):1109-22.
  6. Kong HH, Oh J, Deming C et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 2012; 22: 850-859.
  7. Ruiz R.G., Kemeny D.M., Price J.F. Higher risk of infantile atopic dermatitis from maternal atopy than from paternal atopy // Clin. Exp. Allergy. 1992. Vol. 22. P. 762-766.
  8. Kuo C. L., Chen T. L., Liao C. C., Yeh C. C., Chou C. L., Lee W. R. et al. Birth month and risk of atopic dermatitis: a nationwide population-based study // Allergy. 2016; 71 (11): 1626- 1631.
  9. Tamari M., Tanaka S., Hirota T. Genome-wide association studies of allergic diseases // Allergol. Int. 2013; 62 (1): 21-28.
  10. Liang Y., Chang C., Lu Q. The Genetics and Epigenetics of Atopic Dermatitis-Filaggrin and Other Polymorphisms // Clin Rev Allergy Immunol. 2016; 51 (3): 315-328.
  11. Thyssen J. P., Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis // J Allergy Clin Immunol. 2014; 134 (4): 792-799.
  12. Kabashima K. New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci 2013;70:3-11.
  13. Cork M.J., Robinson D.A., Vasilopoulos Y. et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions // J. Allergy Clin. Immunol. 2006. Vol. 118. P. 3-21.
  14. Kezic S., Kemperman P.M., Koster E.S. et al. Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum // J. Invest. Dermatol. 2008. Vol. 128. P. 1604.
  15. Jihyun Kim, M.D., Ph.D., Byung Eui Kim, M.D., Ph.D., and Donald Y. M. Leung, M.D., Ph.D. Pathophysiology of atopic dermatitis: Clinical implications Allergy Asthma Proc 40:84- 92, 2019
  16. Schultz Larsen F. The epidemiology of atopic dermatitis // Epidemiology of Clinical Allergy / ed. M.L. Burr. Basel : Karger, 1993. P. 9-28.
  17. Grewe M, Bruijnzeel-Koomen CA, Schopf E, Thepen T, Langeveld-Wildschut AG, Ruzicka T, et al. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. // Immunol Today 1998;19:359e61.
  18. Masuoka M, Shiraishi H, Ohta S, Suzuki S, Arima K, Aoki S, et al. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. // J Clin Invest 2012;122:2590e600.
  19. Maksimovic N, Zaric M, Bjelica S, Eric Marinkovic J, Jankovic S. Psychosomatic factors of atopic dermatitis exacerbation. Int J Dermatol. 2018 Sep;57(9):1080-1084.
  20. Lerda, S., & Angelini, G. (2004). Psychosomatic Conditions in Atopic Dermatitis. Dermatology and Psychosomatics / Dermatologie Und Psychosomatik, 5(1), 5-11.
  21. Darlenski R, Kazandjieva J, Hristakieva E, Fluhr JW. Atopic dermatitis as a systemic disease. // Clin Dermatol. 2014 May-Jun;32(3):409-13.
  22. Статистический сборник. Ресурсы и деятельность медицинских организаций дерматовенерологического профиля заболеваемость инфекциями, передаваемыми половым путем, заразными кожными болезнями и заболеваниями кожи за 2017-2018 годы (статистические материалы). РИО: ФГБУ "ЦНИИОИЗ" Минздрава России. Москва. 29019. 208 с.
  23. Статистический сборник. Ресурсы и деятельность медицинских организаций дерматовенерологического профиля. заболеваемость инфекциями, передаваемыми половым путем, заразными кожными болезнями и заболеваниями кожи за 2014-2015 годы (статистические материалы). РИО: ФГБУ "ЦНИИОИЗ" Минздрава России. Москва. 29019. 208 с.
  24. A. Wollenberg, S. Barbarot, T. Bieber, S. Christen-Zaech, M. Deleuran et al. GUIDELINES Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. // JEADV 2018, 32: 657-682
  25. Атопический дерматит. Руководство для врачей под ред. А.А. Баранова, А.А. Кубановой, Л.С. Намазовой-Барановой. - Москва: // ПедиатрЪ, 2017. - 68 с. - (Болезни детского возраста от А до Я/Союз педиатров России [и др.]; вып. 6, 2-е изд.).
  26. Leyden JJ, Marples RR, Kligman AM. 1974. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol 90: 525-530.
  27. Breuer K, HA ̈ussler S, Kapp A, Werfel T. 2002. Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis. // Br J Dermatol 147: 55-61.
  28. Faergemann J. Atopic dermatitis and fungi. // Clin Microbiol Rev. 2002 Oct;15(4):545-63.
  29. Атопический дерматит и экзематозные расстройства / под ред. Дональда Рудикофф, Стивена Р. Коэна, Ноа Шайнфельда ; пер. с англ. под ред. Н. Н. Потекаева, А. Н. Львова. - М. : ГЭОТАР-Медиа, 2017. - 488 с. : ил.
  30. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Suppl) 1980; 92: 44-47.
  31. Lynde C, Barber K, Claveau J, Gratton D, Ho V, Krafchik B, Langley R, Marcoux D, Murray E, Shear N. Canadian practical guide for the treatment and management of atopic dermatitis. // J Cutan Med Surg. 2005;8 Suppl 5:1-9.
  32. Атопический дерматит: Руководство для врачей / Под ред. Ю.В. Сергеева. - М.: Медицина для всех, 2002. - 183 с.
  33. В.Г. Акимов, В.И. Альбанова, И.И. Богатырева, под ред. В.Н. Мордовцева, Г.М. Цветковой. Патология кожи. В 2 т. Т. 2. Частная патоморфология кожи. Стр. 125
  34. Wollenberg A, Barbarot, T.Bieber T et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. // J Eur Acad Dermatol Venereol 2018;32: 657-682.
  35. Sidbury R, Tom WL, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis part 4: prevention of disease flares and use of adjunctive therapies and approaches. // J Am Acad Dermatol 2014;71(6):1218-33.
  36. Giam YC, Hebert AA, Dizon MV, Van Bever H, Tiongco-Recto M, Kim KH, Soebono H,Munasir Z, Diana IA, Luk DC. A review on the role of moisturizers for atopic dermatitis. // Asia Pac Allergy. 2016 Apr;6(2):120-8.
  37. Simpson E, Dutronc Y. A new body moisturizer increases skin hydration and improves atopic dermatitis symptoms among children and adults. // J Drugs Dermatol 2011;10:744-9.
  38. Catherine Mack Correa M, Nebus J. Management of patients with atopic dermatitis: the role of emollient therapy. Dermatol Res Pract 2012;2012:e836931.
  39. Chiang C, Eichenfield LF. Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis. // Pediatr Dermatol 2009; 26(3):273-8.
  40. Wirén K, Nohlgå rd C, Nyberg F, et al. Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. // J Eur Acad Dermatol Venereol 2009;23(11):1267-72.
  41. Cork M. Optimising treatment of atopic dermatitis: the emollient to topical steroid prescribing ratio. Sci Insights Rep 2003.
  42. Palmer CN, Irvine AD, Terron-Kwiatkowski A et al. Common loss-of- function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. // Nat Genet 2006; 38: 441- 446.
  43. Briot A, Deraison C, Lacroix M et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. // J Exp Med 2009; 206: 1135- 1147.
  44. Gelmetti C, Wollenberg A. Atopic dermatitis - all you can do from the outside. // Br J Dermatol 2014; 170 (Suppl 1): 19-24.
  45. Grimalt R, Mengeaud V, Cambazard F, Study Investigators Group. The steroid-sparing effect of an emollient therapy in infants with atopic der- matitis: a randomized controlled study. // Dermatology 2007; 214: 61-67.
  46. Boralevi F, Saint Aroman M, Delarue A et al. Long-term emollient therapy improves xerosis in children with atopic dermatitis. // J Eur Acad Dermatol Venereol 2014; 28: 1456-1462.
  47. Miller DW, Koch SB, Yentzer BA et al. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. // J Drugs Dermatol 2011; 10: 531-537.
  48. Simpson EL, Chalmers JR, Hanifin JM et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. // J Allergy Clin Immunol 2014; 134: 818- 823.
  49. Horimukai K, Morita K, Narita M et al. Application of moisturizer to neonates prevents development of atopic dermatitis. // J Allergy Clin Immunol 2014; 134: 824-830 e6.
  50. Grimalt R, Mengeaud V, Cambazard F, Study Investigators Group. The steroid-sparing effect of an emollient therapy in infants with atopic der- matitis: a randomized controlled study. // Dermatology 2007; 214: 61-67.
  51. Szczepanowska J, Reich A, Szepietowski JC. Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. // Pediatr Allergy Immunol 2008; 19: 614-618.
  52. Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoy- lethanolamine (ATOPA study). // J Eur Acad Dermatol Venereol 2008; 22: 73-82.
  53. Hlela C, Lunjani N, Gumedze F, Kakande B, Khumalo NP. Affordable moisturisers are effective in atopic eczema: a randomised controlled trial. // S Afr Med J 2015; 105: 780-784.
  54. Grimalt R, Mengeaud V, Cambazard F, Study Investigators Group. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. // Dermatology 2007; 214: 61-67.
  55. Weidinger S, Novak N. Atopic dermatitis. // Lancet. 2016;387 (10023):1109-1122.
  56. Hon KL, Kung JSC, Tsang KYC, Yu JWS, Lee VW. Leung TF. Emollient Acceptability in Childhood Atopic Dermatit : Not All Emollients are Equal. // Curr Pediatr Rev. 2018;14(2):117122.
  57. Kamata Y, Tominaga M, Takamori K Itch in atopic dermatitis management // Curr Prob Dermatol2016; 50:86-93.
  58. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. // Br J Dermatol 2002; 147: 528-537.
  59. Berth-Jones J, Damstra RJ, Golsch S et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. // BMJ 2003; 326: 1367.
  60. Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. // Br J Dermatol 1999; 140: 1114-1121.
  61. Peserico A, Stadtler G, Sebastian M, Fernandez RS, Vick K, Bieber T. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. // Br J Dermatol 2008; 158: 801-807.
  62. Sher LG, Chang J, Patel IB, Balkrishnan R, Fleischer AB Jr. Relieving the pruritus of atopic dermatitis: a meta-analysis. // Acta Derm Venereol 2012; 92: 455-461.
  63. Yasuda T. Clinical experiences with hydrocortisone 17-butyrate. // Dermatologica 1976; 152 (suppl.1):221-229.
  64. Juhlin L. Comparison of fluticasone propionate cream, 0.05%, and hydrocortisone-17butyrate cream, 0.1%, in the treatment of eczema. // Cutis. 1996 Feb;57(2 Suppl):51-6.
  65. Falk ES, Giannetti A, Rampen FHJ, Woerdeman MJ, Pinto Soares AL. A new formulation of hydrocortisone 17-butyrate for the treatment of steroid responsive dermatoses. // Dtsch Dermatol 1994; 42(7):744-750.
  66. Abramovits W, Oquendo M. Hydrocortisone butyrate 0.1% lipocream in pediatric patients with atopic dermatitis. // Skinmed. 2010 Mar-Apr; 8(2):72-9.
  67. Fritsch P. Clinical experience with methylprednisolone aceponate (MPA) in eczema. // Journal of Dermatological Treatment 1992; 3 (Suppl.2)17-19.
  68. BlumePeytavi, U. and Wahn, U. (2011), Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone aceponate. Journal of the European Academy of Dermatology and Venereology, 25: 508-515.
  69. Meurer M, Eichenfield LF, Ho V, Potter PC, Werfel T, Hultsch T. Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: a randomized, double-blind trial. // J Dermatolog Treat 2010; 21: 157-166.
  70. Carr, W.W. Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations. Pediatr Drugs 15, 303-310 (2013)
  71. Yin ZQ, Zhang WM, Song GX, Luo D. Meta-analysis on the comparison between two topical calcineurin inhibitors in atopic dermatitis. // J Dermatol. 2012 Jun; 39(6):520-6
  72. Svensson A, Chambers C, Gånemo A, Mitchell SA. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. // Curr Med Res Opin. 2011 Jul; 27(7):1395-406.
  73. Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM. Topical tacrolimus for atopic dermatitis. // Cochrane Database Syst Rev. 2015 Jul 1; (7):CD009864.
  74. El-Batawy MM, Bosseila MA, Mashaly HM, Hafez VS. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. // J Dermatol Sci. 2009 May;54(2):76- 87.
  75. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. // BMJ. 2005 Mar 5;330(7490): 516.
  76. Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. // Br J Dermatol 2011; 164: 415-428.
  77. Wollenberg A, Ehmann LM. Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol 2012; 24: 253-260.
  78. Thaçi, D., Reitamo, S., Gonzalez Ensenat, M., Moss, C., Boccaletti, V., Cainelli, T., Van Der Valk, P., Buckova, H., Sebastian, M., Schuttelaar, M., Ruzicka, T. and (2008), Proactive disease management with 0·03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. British Journal of Dermatology, 159: 1348-1356.
  79. Фассахов Р.С., Пампура А.Н., Коростовцев Д.С. и др. Эффективность и безопасность активированного цинк пиритиона (скин-кап) в лечении атопического дерматита у детей (результаты Российского многоцентрового исследования). // Вестник педиатрической фармакологии и нутрициологии 2006; 3 (6): 28-31.
  80. Нейродерматозы. В кн.: Кожные и венерические болезни: Руководство для врачей. В двух томах. - 2-е изд., перераб. и доп. - Т.2/ Под ред. Ю.К. Скрипкина и В.Н. Мордовцева, - М.: Медицина, 1999. - С.9-49.
  81. Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. // Br J Dermatol 2010; 163: 12-26.
  82. Francis NA, Ridd MJ, Thomas-Jones E, Shepherd V, Butler CC, Hood K, Huang C, Addison K, Longo M, Marwick C, Wootton M, Howe R, Roberts A, Haq MI, Madhok V, Sullivan F; CREAM team. A randomised placebo-controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. // Health Technol Assess. 2016 Mar; 20(19):i-xxiv, 1-84.
  83. Lever, R., Hadley, K., Downey, D. and Mackie, R. (1988), Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. British Journal of Dermatology, 119: 189-198.
  84. Кениксфест Ю.В., Кохан М.М., Стукова Е.И. Клиническая эффективность применения препарата Банеоцин в детской дерматологической практике. Педиатрия (Прил. к журн. Consilium Medicum). 2018; 1: 126-131.
  85. Короткий Н.Г., Шарова Н.М., Сидоренко О.А. Банеоцин в терапии осложненных форм атопического дерматита у детей. Клин. дерматология и венерология. 2006; 1: 97-100.
  86. Larsen FS, Simonsen L, Melgaard A, Wendicke K, Henriksen AS. An efficient new formulation of fusidic acid and betamethasone 17-valerate (fucicort lipid cream) for treatment of clinically infected atopic dermatitis. // Acta Derm Venereol. 2007;87(1):62-8.
  87. Ramsay CA, Savoie JM, Gilbert M, Gidon M, Kidson P. The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. // J Eur Acad Dermatol Venereol 1996; 7 Suppl 1: S15-S22
  88. Кравченя СС, Игонина ИА, Бакулев АЛ. Комбинированная наружная терапия атопического дерматита. // Клиническая Дерматология и Венерология 2011; 1:41-44.
  89. Diepgen TL. Early Treatment of the Atopic Child Study Group. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebocontrolled trial (the ETAC trial) over 18 months. // Pediatr Allergy Immunol 2002;13:278-86. 90.
  90. Herman, S. M., & Vender, R. B. (2003). Antihistamines in the Treatment of Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology, 7(6), 467-473.
  91. Klein PA, Clark RA. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. // Arch Dermatol 1999;135:1522-5.
  92. Hannuksela M, Kalimo K, Lammintausta K, Mattila T, Turjanmaa K, Varjonen E, et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. // Ann Allergy 1993;70:127-33.
  93. Epstein E, Pinski JB. A blind study. // Arch Dermatol 1964;89: 548-9.
  94. Simons FE. Early Prevention of Asthma in Atopic Children Study G. Safety of levocetirizine treatment in young atopic children: an 18-month study. // Pediatr Allergy Immunol 2007; 18: 535-542.
  95. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. // Br J Dermatol 2003; 148: 1212-1221.
  96. van Zuuren EJ, Apfelbacher CJ, Fedorowicz Z, Jupiter A, Matterne U, Weisshaar E. No high level evidence to support the use of oral H1 antihistamines as monotherapy for eczema: a summary of a Cochrane systematic review. Syst Rev 2014; 3: 25.
  97. Hannuksela M, Kalimo K, Lammintausta K et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. // Ann Allergy 1993; 70: 127-133.
  98. Kircik L: Management of pruritus with levocetirizine dihydrochloride in atopic dermatitis in a randomized, double-blind, placebo controlled study - interim analysis of 21 subjects. Western Society of Allergy, Asthma, and Immunology Meeting Lnai, HI United States, 24-28 January 2010. // Allergy Asthma Proc 2010, 31:166.
  99. Петрова К.С., Петрова Г.А. Хлоропирамин (Супрастин) - современные аспекты применения в терапии аллергодерматозов. Русский медицинский журнал. Фармакотерапия. 2014; 8: 617-620.
  100. Горячкина М.В,, Белоусова Т.А. Хлоропирамин: клинические аспекты применения. Русский медицинский журнал. Аллергология. 2014; 24: 1785-1789.
  101. Ревякина В.А. Антигистаминные препараты в клинической практике. Русский медицинский журнал. Аллергология. 2014; 11: 854-856.
  102. Попова И.С., Матушевская Е.В., Свирщевская Е.В. Двойное слепое плацебо- контролируемое исследование эффективности и переносимости кларотадина при атопическом дерматите. Русс. Мед. Журн. Дерматология, Венерология. 2001; 9 (4): 477- 483.
  103. Кубанова А. А. (ред.) Федеральные клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путём. 5-е изд., перераб. и доп. М.: Деловой экспресс. 2016; с. 62-65
  104. Monroe E.W. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther 1992; 14 (1): 17-21.
  105. Langeland T., Fagertun H.E., Larsen S. Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis. A multi-crossover-designed study. Allergy 1994; 49 (1): 22-26. 106.
  106. Czech W, Brautigam M, Weidinger G, Schopf E. A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol 2000; 42: 653-659.
  107. Van der Schaft J, Politiek K, van den Reek JM et al. Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis. // Br J Dermatol 2015; 172: 1621-1627.
  108. Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P, Cork MJ, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. // Br J Dermatol 2000; 142:52-8.
  109. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczemaea systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007;21:606-19. 110.
  110. Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. // J Allergy Clin Immunol 2014; 133: 429-38.
  111. John Berth-Jones, Andrew Y Finlay, Irshad Zaki, Boon Tan, Helen Goodyear, Susan Lewis-Jones, Michael J Cork, Stanley S Bleehen, M.Sam Salek, B.Roger Allen, Peter Friedmann, John Harper, Richard D.R Camp, Steven Smith, Robin A.C Graham-Brown, Cyclosporine in severe childhood atopic dermatitis: A multicenter study, Journal of the American Academy of Dermatology, Volume 34, Issue 6,1996, Pages 1016-1021.
  112. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, Chamlin SL, Cooper KD, Feldman SR, Hanifin JM, Krol A, Margolis DJ, Paller AS, Schwarzenberger K, Silverman RA, Simpson EL, Tom WL, Williams HC, Elmets CA, Block J, Harrod CG, Begolka WS, Eichenfield LF; American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. // J Am Acad Dermatol. 2014 Aug;71(2):327-49.
  113. Schmitt J, Schakel K, Folster-Holst R, Bauer A, Oertel R, Augustin M, et al. Prednisolone vs cyclosporin for severe adult eczema: an investigator-initiated double-blind placebo-controlled multicenter trial. // Br J Dermatol 2010; 162:661-8.
  114. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis), part II. // J Eur Acad Dermatol Venereol 2012;26:1176-93.
  115. Vangipuram R, Tyring SK. Dupilumab for Moderate-to-Severe Atopic Dermatitis. // Skin Therapy Lett. 2017 Nov;22(6):1-4.
  116. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V,Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. // N Engl J Med. 2016 Dec 15; 375(24): 23352348.
  117. Blauvelt A., de Bruin-Weller M., Gooderham M. et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. // Lancet 2017; 389 (10086): 2287-2303.
  118. de Bruin-Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebocontrolled, randomized phase III clinical trial (LIBERTY AD CAFÉ). // Br J Dermatol. 2018 May; 178(5):1083-1101.
  119. Thaçi D., L Simpson E., Deleuran M. et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). // J Dermatol Sci. 2019; 94 (2): 266-275.
  120. Cork M.J., Eckert L., Simpson E.L. et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. // J Dermatolog Treat. 2019 Jun 9:1-9.
  121. Snast I, et al. Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis. // Am J Clin Dermatol. 2018 Apr;19(2):145-165.
  122. Wang FP, et al. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. // J Dermatol Sci. 2018 May;90(2):190-198.
  123. Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials. // J Am Acad Dermatol. 2018 Jan;78 (1):62-69.e1.
  124. Diagnosis and Management of Difficult-to-treat and Severe Asthma in adolescent and adult patients. A GINA pocket guide for health professionals V2.0. April 2019. Электронный ресурс: www.ginasthma.org.
  125. Thaci D, Simpson EL, Beck LA et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, doseranging phase 2b trial. Lancet 2016; 387: 40-52. 67 Simpson EL, Bieber T, Guttman-Yassky E et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. // N Engl J Med 2016; 375: 2335-2348.
  126. Boguniewicz M, Sampson H, Leung SB, Harbeck R, Leung DY. Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. // J Allergy Clin Immunol 2001;108:651-2.
  127. Murakami K, Fujioka T, Nishizono A, Nagai J, Tokieda M, Kodama R, Kubota T, Nasu M. Atopic dermatitis successfully treated by eradication of Helicobacter pylori. // J Gastroenterol. 1996 Nov;31 Suppl 9:77-82.
  128. Petry V., Bessa G.R., Poziomczyck C.S. et al. Bacterial skin colonization and infections in patients with atopic dermatitis. An Bras Dermatol. 2012; 87 (5): 729-734.
  129. Тренева М.С., and Пампура А.Н.. "Стратегия выбора антибактериальных препаратов у детей c микробным инфицированием атопического дерматита" Практическая медицина, no. 51, 2011, pp. 136-139.
  130. Niebuhr, M., Mai, U., Kapp, A., & Werfel, T. (2008). Antibiotic treatment of cutaneous infections with Staphylococcus aureusin patients with atopic dermatitis: current antimicrobial resistances and susceptibilities. Experimental Dermatology, 17(11), 953-957.
  131. Kolmer, H., Taketomi, E., Hazen, K., Hughs, E., Wilson, B., & Plattsmills, T. (1996). Effect of combined antibacterial and antifungal treatment in severe atopic dermatitis. // Journal of Allergy and Clinical Immunology, 98(3), 702-707.
  132. Morison WL, Parrish J, Fitzpatrick TB. Oral psoralen photochemotherapy of atopic eczema. // Br J Dermatol 1978;98:25-30.
  133. Meduri NB, Vandergriff T, Rasmussen H, Jacobe H. Phototherapy in the management of atopic dermatitis: a systematic review. Photodermatol Photoimmunol Photomed 2007;23:106-12.
  134. Rombold S, Lobisch K, Katzer K, Grazziotin TC, Ring J, Eberlein B. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. // Photodermatol Photoimmunol Photomed 2008; 24:19-23.
  135. Clayton TH, Clark SM, Turner D, Goulden V. The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. // Clin Exp Dermatol 2007;32:28-33.
  136. Jekler J, Larko O. UVB phototherapy of atopic dermatitis. // Br J Dermatol 1988;119:697705.
  137. Grundmann-Kollmann M, Behrens S, Podda M, Peter RU, Kaufmann R, Kerscher M. Phototherapy for atopic eczema with narrow-band UVB. J Am Acad Dermatol 1999;40:995-7.
  138. Tay YK, Morelli JG, Weston WL. Experience with UVB phototherapy in children. // Pediatr Dermatol 1996;13:406-9.
  139. Uetsu N, Horio T. Treatment of persistent severe atopic dermatitis in 113 Japanese patients with oral psoralen photo-chemotherapy. // J Dermatol 2003;30:450-7.
  140. Yoshiike T, Aikawa Y, Sindhvananda J, Ogawa H. A proposed guideline for psoralen photochemotherapy (PUVA) with atopic dermatitis: successful therapeutic effect on severe and intractable cases. // J Dermatol Sci 1993;5:50-3.
  141. Atherton DJ, Carabott F, Glover MT, Hawk JL. The role of psoralen photochemotherapy (PUVA) in the treatment of severe atopic eczema in adolescents. Br J Dermatol 1988;118: 791-5.
  142. Jury CS, McHenry P, Burden AD, Lever R, Bilsland D. Narrowband ultraviolet B (UVB) phototherapy in children. // Clin Exp Dermatol 2006;31:196-9.
  143. Tzung TY, Lin CB, Chen YH, Yang CY. Pimecrolimus and narrowband UVB as monotherapy or combination therapy in children and adolescents with atopic dermatitis. // Acta Derm Venereol 2006; 86:34-8.
  144. Kemeny L, Varga E, Nova KZ Advances in phototherapy for psoriasis and atopic dermatitis Expert Rew // Clin Immunol 2019; Nov 15 (11): 1205-1214)
  145. Schneider L, Tilles S, Lio P, Boguniewcz M, Beck I, Lebovidge J et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013;131:295-9:e1-27.
  146. Zandi S, Kalia S, Lui H. UVA1 phototherapy: a concise and practical review. // Skin Therapy Lett. 2012 Jan; 17(1):1-4.
  147. Mehraban S, Feily A 308 nm excimer laser in dermatology // J lasers Med Sci 2014 Winter ; 5(1):8-12
  148. Аллергология. Федеральные клинические рекомендации. Под ред. Р.М. Хаитова, Н.И. Ильиной. М. "ФАРМА- РУС ПРИНТ МЕДИА". 2014, с. 69-89.
  149. Ring J, Alomar A, Bieber T et al., Guidelines for treatment of atopic eczema (atopic dermatitis) Part I. // J Eur Acad Dermatol Venereol. 2012 Aug;26(8):1045-60.
  150. Боровик Т.Э., Ревякина В.А., Макарова С.Г. Диетотерапия при пищевой аллергии у детей раннего возраста. // Российский Аллергологический журнал №4, 2004г.
  151. Bath-Hextall FJ, Jenkinson C, Humphreys R, Williams Hywel C. Dietary supplements for established atopic eczema. // Cochrane Database Syst Rev 2012; 2: CD005205.
  152. Атопический дерматит/ В.И. Альбанова, А.Н. Пампура. - М: ГЭОТАР-Медиа, 2014. - 128 с.: цв. вкл.
  153. Heratizadeh A, Werfel T, Wollenberg A, Abraham S, Plank-Habibi S, Schnopp C,Sticherling M, Apfelbacher C, Biedermann T, Breuer K, Fell I, Fölster-Holst R,Heine G, Grimm J, Hennighausen L, Kugler C, Reese I, Ring J, Schäkel K, Schmitt J, Seikowski K, von Stebut E, Wagner N, Waßmann-Otto A, Wienke-Graul U, Weisshaar E, Worm M, Gieler U, Kupfer J; Arbeitsgemeinschaft Neurodermitisschulung für Erwachsene (ARNE) Study Group. Effects of structured patient education in adults with atopic dermatitis: Multicenter randomized controlled trial. J Allergy Clin Immunol. 2017 Sep;140(3):845-853.e3.
  154. Антоньев А.А., Шеварова В.Н., Гребенников В.А., Ометов В.К. Врачебно-трудовая экспертиза и диспансеризация при дерматозах. Ростов-на-Дону: изд-во Ростовского ун-та, 1996; 240 с.
  155. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. - 1993 - Vol 186 - N 1 - P. 23-31.
  156. Pucci N, Novembre E, Cammarata MG, Bernardini R, Monaco MG, Calogero C, Vierucci A. Scoring atopic dermatitis in infants and young children: distinctive features of the SCORAD index. // Allergy. 2005 Jan;60(1):113-6.
  157. C. Charman, C. Chambers, and H. Williams, “Measuring atopic dermatitis severity in randomized controlled clinical trials: what exactly are we measuring?” // Journal of Investigative Dermatology, 2003: 120 (6); 932-941.
  158. "Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis". // Dermatology (Basel) 1993; 186 (1): 23-31.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*